TORONTO and HOUSTON,
May 29, 2018 /PRNewswire/ - Medicenna
Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA;
OTCQX: MDNAF), a clinical stage immuno-oncology company, is pleased
to announce that executives from Medicenna will attend and present
at the upcoming 4th Annual Sachs Immuno-Oncology:
BD&L and Investment Forum being held on June 1, 2018 in Chicago, in parallel with the Annual Meeting
of the American Society of Clinical Oncology (ASCO).
Dr. Fahar Merchant, President and
CEO of Medicenna, will provide an overview of the Company, its most
recent accomplishments and upcoming milestones with a focus on its
IL-2 Superkine (MDNA109) and IL-4 Empowered Cytokine (MDNA55)
programs. MDNA109, in pre-clinical development, is the only
engineered IL-2 Superkine designed to specifically target CD122
(IL-2Rβ) without CD25 dependency. Unlike native IL-2, MDNA109
potently stimulates effector T cells, reverses Natural Killer (NK)
cell anergy and acts with exceptional synergy when combined with
checkpoint inhibitors. Lead selection of MDNA109 with extended
half-life characteristics is currently underway. MDNA55, a fusion
toxin targeting the IL-4R which is over-expressed in brain cancer
and its immunosuppressive tumor micro-environment, is currently
enrolling in a Phase 2b recurrent
glioblastoma (rGBM) trial at major centers in the US.
Details of the June 1, 2018
presentation:
Sachs Associates 4th Annual Immuno-Oncology: BD&L and
Investment Forum
Date:
|
June 1,
2018
|
Time:
|
3:40 pm Central
Time
|
Track:
|
B
|
Location:
|
Faulkner Room,
Waldorf Astoria Chicago Hotel, Chicago, Illinois, USA
|
About Medicenna Therapeutics
Medicenna is a clinical
stage immuno-oncology company developing novel highly selective
versions of IL-2, IL-4 and IL-13 Superkines™ and first in class
Empowered Cytokines™ (ECs). Medicenna is specifically
targeting the Interleukin-4 Receptor (IL4R), which is
over-expressed by at least 20 different types of cancer affecting
more than one million new cancer patients every year. A Phase
2b clinical trial for recurrent
glioblastoma (rGBM) is enrolling patients at leading brain cancer
centres in the US using Medicenna's lead candidate MDNA55. MDNA55
has completed 3 clinical trials in 72 patients, including 66 adults
with rGBM, demonstrated compelling efficacy and obtained Fast-Track
and Orphan Drug status from USFDA. Unlike most other cancer
therapies, Medicenna's MDNA55 has the potential to purge both the
tumor and the immunosuppressive tumor microenvironment, offering a
unique treatment paradigm for a large majority of cancer
patients.
For more information, please visit www.medicenna.com.
This news release contains forward-looking statements
relating to the future operations of the Company and other
statements that are not historical facts. Forward-looking
statements are often identified by terms such as "will", "may",
"should", "anticipate", "expects" and similar expressions. All
statements other than statements of historical fact, included in
this release, including, without limitation, statements regarding
future plans and objectives of the Company, are forward-looking
statements that involve risks and uncertainties. There can be no
assurance that such statements will prove to be accurate and actual
results and future events could differ materially from those
anticipated in such statements. Important factors that could cause
actual results to differ materially from the Company's expectations
include the risks detailed in the annual information form of the
Company dated June 15, 2017 and in
other filings made by the Company with the applicable securities
regulators from time to time.
The reader is cautioned that assumptions used in the
preparation of any forward-looking information may prove to be
incorrect. Events or circumstances may cause actual results to
differ materially from those predicted, as a result of numerous
known and unknown risks, uncertainties, and other factors, many of
which are beyond the control of the Company. The reader is
cautioned not to place undue reliance on any forward-looking
information. Such information, although considered reasonable by
management at the time of preparation, may prove to be incorrect
and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are
expressly qualified by this cautionary statement. The
forward-looking statements contained in this news release are made
as of the date of this news release and the Company will update or
revise publicly any of the included forward-looking statements only
as expressly required by Canadian securities law.
View original
content:http://www.prnewswire.com/news-releases/medicenna-to-present-at-4th-annual-immuno-oncology-bdl-and-investment-forum-300655552.html
SOURCE Medicenna Therapeutics Corp.